Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Alder Biopharma Raises US$38 Million In Series D Financing 11
Licensing Agreements 13
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14
Equity Offering 15
Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18
Alder BioPharma Raises USD230 Million in Public Offering of Shares 20
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22
Alder Biopharma Raises USD88.8 Million in IPO 24
Debt Offering 26
Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26
Alder Biopharmaceuticals Inc – Key Competitors 28
Alder Biopharmaceuticals Inc – Key Employees 29
Alder Biopharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 05, 2018: Alder BioPharmaceuticals reports third quarter 2018 financial and operating results 31
Aug 07, 2018: Alder BioPharmaceuticals reports second quarter 2018 financial and operating results 32
May 08, 2018: Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results 33
Feb 26, 2018: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 34
Nov 07, 2017: Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 36
Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 37
Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 39
Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 41
Corporate Communications 43
Apr 26, 2018: Alder BioPharmaceuticals Appoints Jeremy Green to its Board of Directors 43
Apr 16, 2018: Alder BioPharmaceuticals Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer 44
Mar 20, 2018: Alder BioPharmaceuticals Appoints Paul B. Cleveland as Interim President and Chief Executive Officer 45
Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 46
Product News 47
03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 47
Clinical Trials 48
Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 48
Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 49
Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alder Biopharma Raises US$38 Million In Series D Financing 11
Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13
Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14
Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15
Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16
Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18
Alder BioPharma Raises USD230 Million in Public Offering of Shares 20
Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22
Alder Biopharma Raises USD88.8 Million in IPO 24
Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26
Alder Biopharmaceuticals Inc, Key Competitors 28
Alder Biopharmaceuticals Inc, Key Employees 29
Alder Biopharmaceuticals Inc, Subsidiaries 30
List of Figures
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9